{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:01:11Z","timestamp":1781650871816,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81001189"],"award-info":[{"award-number":["81001189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81071851"],"award-info":[{"award-number":["81071851"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2018A030313292"],"award-info":[{"award-number":["2018A030313292"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2016A030313768"],"award-info":[{"award-number":["2016A030313768"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"crossref","award":["201804010430"],"award-info":[{"award-number":["201804010430"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"crossref","award":["201707010418"],"award-info":[{"award-number":["201707010418"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Anti-Cancer Association-HER2 Target China Scientific Research Fund","award":["CORP-239-S24"],"award-info":[{"award-number":["CORP-239-S24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05037-6","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:54:41Z","timestamp":1777334081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenic germline variants associated with different HER2 expression among breast cancer patients"],"prefix":"10.1007","volume":"17","author":[{"given":"Yongqi","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheukfai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiaopei","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Balch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Weitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-405X","authenticated-orcid":false,"given":"Jiayan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"5037_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024; 74: 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA: A Cancer J Clin"},{"key":"5037_CR2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"5037_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong GM, Cullen GD, O\u2019Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. Cancer J Clin. 2020;70:355\u201374. https:\/\/doi.org\/10.3322\/caac.21634.","journal-title":"Cancer J Clin"},{"key":"5037_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6.","journal-title":"Lancet Oncol"},{"key":"5037_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"5037_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887\u201396. https:\/\/doi.org\/10.1200\/JCO.19.02318.","journal-title":"J Clin Oncol"},{"key":"5037_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022;20:142. https:\/\/doi.org\/10.1186\/s12916-022-02346-9.","journal-title":"BMC Med"},{"key":"5037_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, et al. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N Engl J Med. 2021;384:428\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1913948.","journal-title":"N Engl J Med"},{"key":"5037_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384:440\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2005936.","journal-title":"N Engl J Med"},{"key":"5037_CR10","doi-asserted-by":"publisher","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"Breast Cancer Association","year":"2022","unstructured":"Breast Cancer Association. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8:e216744. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6744.","journal-title":"JAMA Oncol"},{"key":"5037_CR11","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/humu.24060","volume":"41","author":"C Fortuno","year":"2020","unstructured":"Fortuno C, et al. Suggested application of HER2\u2009+\u2009breast tumor phenotype for germline TP53 variant classification within ACMG\/AMP guidelines. Hum Mutat. 2020;41:1555\u201362. https:\/\/doi.org\/10.1002\/humu.24060.","journal-title":"Hum Mutat"},{"key":"5037_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1186\/s12885-020-07476-y","volume":"20","author":"A Kwong","year":"2020","unstructured":"Kwong A, et al. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020;20:1053. https:\/\/doi.org\/10.1186\/s12885-020-07476-y.","journal-title":"BMC Cancer"},{"key":"5037_CR13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nmeth.3622","volume":"12","author":"W Zhou","year":"2015","unstructured":"Zhou W, et al. TransVar: a multilevel variant annotator for precision genomics. Nat Methods. 2015;12:1002\u20133. https:\/\/doi.org\/10.1038\/nmeth.3622.","journal-title":"Nat Methods"},{"key":"5037_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/genes11050585","author":"X Renaudin","year":"2020","unstructured":"Renaudin X, Rosselli F The FANC\/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links. Genes (Basel). 2020. . https:\/\/doi.org\/10.3390\/genes11050585.","journal-title":"Genes (Basel)"},{"key":"5037_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"5037_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-020-05778-0","volume":"183","author":"K Li","year":"2020","unstructured":"Li K, et al. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. Breast Cancer Res Treat. 2020;183:321\u201332. https:\/\/doi.org\/10.1007\/s10549-020-05778-0.","journal-title":"Breast Cancer Res Treat"},{"key":"5037_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12282-021-01289-y","volume":"29","author":"J Lai","year":"2022","unstructured":"Lai J, et al. Integrated analysis of cell cycle-related genes in HR+\/HER2- breast cancer. Breast Cancer. 2022;29:121\u201330. https:\/\/doi.org\/10.1007\/s12282-021-01289-y.","journal-title":"Breast Cancer"},{"key":"5037_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.21037\/atm.2019.04.23","volume":"7","author":"G Zhang","year":"2019","unstructured":"Zhang G, et al. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Ann Transl Med. 2019;7:179. https:\/\/doi.org\/10.21037\/atm.2019.04.23.","journal-title":"Ann Transl Med"},{"key":"5037_CR19","doi-asserted-by":"publisher","first-page":"144970","DOI":"10.1016\/j.gene.2020.144970","volume":"759","author":"L Guo","year":"2020","unstructured":"Guo L, et al. The transcription factor CBFB mutations indicate an improved survival in HR+\/HER2- breast cancer. Gene. 2020;759:144970. https:\/\/doi.org\/10.1016\/j.gene.2020.144970.","journal-title":"Gene"},{"key":"5037_CR20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/1759-7714.13467","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, et al. Impact of TP53 mutations in breast cancer: clinicopathological features and prognosisImpact of TP53 mutations in breast CA. Thorac Cancer. 2020;11:1861\u20138. https:\/\/doi.org\/10.1111\/1759-7714.13467.","journal-title":"Thorac Cancer"},{"key":"5037_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21037\/cco.2016.05.10","volume":"5","author":"N Liao","year":"2016","unstructured":"Liao N. HER2-positive breast cancer, how far away from the cure?-on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients. Chin Clin Oncol. 2016;5:41. https:\/\/doi.org\/10.21037\/cco.2016.05.10.","journal-title":"Chin Clin Oncol"},{"key":"5037_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12916-022-02284-6","volume":"20","author":"R Tan","year":"2022","unstructured":"Tan R, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022;20:105. https:\/\/doi.org\/10.1186\/s12916-022-02284-6.","journal-title":"BMC Med"},{"key":"5037_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13058-024-01899-2","volume":"26","author":"G Nader-Marta","year":"2024","unstructured":"Nader-Marta G, et al. Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42\/AFT-05\/BIG-14-13\/PrE0109). Breast Cancer Res. 2024;26:140. https:\/\/doi.org\/10.1186\/s13058-024-01899-2.","journal-title":"Breast Cancer Res"},{"key":"5037_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13000-024-01557-3","volume":"19","author":"F Guan","year":"2024","unstructured":"Guan F, et al. Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer. Diagn Pathol. 2024;19:131. https:\/\/doi.org\/10.1186\/s13000-024-01557-3.","journal-title":"Diagn Pathol"},{"key":"5037_CR25","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.modpat.2025.100778","volume":"38","author":"D Jiao","year":"2025","unstructured":"Jiao D, et al. Impact of hormone receptor status and HER2 expression on neoadjuvant targeted therapy response in HER2-positive breast cancer: a multicenter retrospective study. Mod Pathol. 2025;38:100778. https:\/\/doi.org\/10.1016\/j.modpat.2025.100778.","journal-title":"Mod Pathol"},{"key":"5037_CR26","doi-asserted-by":"publisher","first-page":"114307","DOI":"10.1016\/j.ejca.2024.114307","volume":"211","author":"M Bottosso","year":"2024","unstructured":"Bottosso M, et al. HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. Eur J Cancer. 2024;211:114307. https:\/\/doi.org\/10.1016\/j.ejca.2024.114307.","journal-title":"Eur J Cancer"},{"key":"5037_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","volume":"330","author":"AW Kurian","year":"2023","unstructured":"Kurian AW, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330:43\u201351. https:\/\/doi.org\/10.1001\/jama.2023.9526.","journal-title":"JAMA"},{"key":"5037_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","volume":"110","author":"R Manchanda","year":"2018","unstructured":"Manchanda R, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018;110:714\u201325. https:\/\/doi.org\/10.1093\/jnci\/djx265.","journal-title":"J Natl Cancer Inst"},{"key":"5037_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, et al. Germline testing in patients with breast cancer: ASCO-society of surgical oncology guideline. J Clin Oncol. 2024;42:584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225.","journal-title":"J Clin Oncol"},{"key":"5037_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrm.2016.48","volume":"17","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Sarangi P, D\u2019Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17:337\u201349. https:\/\/doi.org\/10.1038\/nrm.2016.48.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5037_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","volume":"3","author":"J Niraj","year":"2019","unstructured":"Niraj J, F\u00e4rkkil\u00e4 A, D\u2019Andrea AD. The fanconi anemia pathway in cancer. Annu Rev Cancer Biol. 2019;3:457\u201378. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030617-050422.","journal-title":"Annu Rev Cancer Biol"},{"key":"5037_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fcell.2020.00160","volume":"8","author":"CB Fang","year":"2020","unstructured":"Fang CB, Wu HT, Zhang ML, Liu J, Zhang GJ. Fanconi anemia pathway: mechanisms of breast cancer predisposition development and potential therapeutic targets. Front Cell Dev Biol. 2020;8:160. https:\/\/doi.org\/10.3389\/fcell.2020.00160.","journal-title":"Front Cell Dev Biol"},{"key":"5037_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/ng1902","volume":"38","author":"S Seal","year":"2006","unstructured":"Seal S, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239\u201341. https:\/\/doi.org\/10.1038\/ng1902.","journal-title":"Nat Genet"},{"key":"5037_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165\u20137. https:\/\/doi.org\/10.1038\/ng1959.","journal-title":"Nat Genet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05037-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:49:38Z","timestamp":1781650178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5037"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05037-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethics Committee at Guangdong Provincial People\u2019s Hospital (Nos. KY2025-959-01). The patient signed a written informed consent for participation. This study adhered to the Declaration of Helsinki. This study was conducted in accordance with relevant institutional and national guidelines for research on human genetic data. All identifying and sensitive information was removed from the data prior to analysis, ensuring complete anonymization. No ethical or regulatory conflicts apply due to the use of fully de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as the study does not include any identifiable images or personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"888"}}